Welcome to our dedicated page for Concord Medical SEC filings (Ticker: CCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Navigating SEC filings for foreign healthcare companies requires understanding a different disclosure framework. Concord Medical Services (CCM) files as a foreign private issuer, meaning its regulatory documents follow international reporting standards rather than U.S. GAAP conventions that domestic healthcare stocks use.
The company's Form 20-F annual report provides comprehensive insight into its radiotherapy and diagnostic imaging operations across China. Unlike a standard 10-K, this document includes reconciliations between international and U.S. accounting standards, offering a detailed view of how segment revenues from network partnerships and hospital operations translate into comparable metrics.
Form 6-K filings serve as Concord Medical's equivalent to 8-K material event disclosures. These reports cover significant developments: shareholder meeting announcements, financial results releases, and updates on treatment capabilities such as proton therapy implementations. Tracking 6-K filings helps investors stay informed about operational progress between annual reports.
Our AI tools simplify analysis of Concord Medical's international filings by highlighting key financial metrics, explaining accounting treatment differences, and flagging material developments. Whether you're researching the company's network segment performance or tracking new treatment center announcements, automated summaries save hours of manual document review.
Access insider transaction records through Form 4 filings to monitor when executives and directors adjust their holdings. Combined with 6-K event disclosures and comprehensive 20-F annual reports, these documents provide the complete regulatory picture for evaluating this China-focused oncology services provider.
Concord Medical Services Holdings Ltd. (NYSE: CCM) has filed a Form 6-K to disclose that its Hong Kong–listed subsidiary, Concord Healthcare Group Co., Ltd. (HKSE: 2453.HK), signed a placing agreement on 22 July 2025 with Guotai Junan Securities (Hong Kong). Under the agreement the placing agent will, on a best-effort basis, place 48,723,600 new H-shares with at least six independent investors at HK$5.54 per share. The issuance will be made under Concord Healthcare’s existing general mandate. No financial statements, earnings figures or projected proceeds were provided in the filing.
The transaction increases Concord Healthcare’s share count and is intended to raise fresh capital for the subsidiary; however, the filing does not state the specific use of proceeds or anticipated dilution for Concord Medical’s shareholders. The parent reiterates that additional details on the subsidiary’s Hong Kong transactions can be found on the HKEX website.
Concord Medical Services Holdings Limited (NYSE: CCM) filed a Form 6-K to disclose that its Hong Kong–listed subsidiary, Concord Healthcare Group Co., Ltd. (HKSE: 2453.HK), experienced a reduction in the stake held by one of its controlling shareholders. On 20 June 2025, Beijing Concord Medical Technology Co., Ltd. sold 32,800,000 H shares of Concord Healthcare via block trade at HK$6.12 per share, equal to approximately 4.46 % of Concord Healthcare’s issued share capital. The filing reiterates that Concord Healthcare’s H shares were listed on the HKSE on 9 January 2024 and directs investors to the HKSE website for transaction details.
No additional financial results, earnings data or strategic initiatives were reported in this 6-K.
FAQ
What is the current stock price of Concord Medical (CCM)?
What is the market cap of Concord Medical (CCM)?
